Akili: Prescription digital therapeutics company (PDT) with EndeavorRx, the first FDA-cleared video game treatment option for ADHD (pediatric patients). Company focused on using its digital technology for diseases and chronic illnesses associated with cognition. The company set commercial launch for EndeavorRx for 2H 2022. Akili has projected $500M sales potential for EndeavorRx from the US ADHD market achievable ~5-7 years post-launch. Expected clinical data releases in 2023 including US pivotal data for EndeavorRx in 13-17 year-old pediatric ADHD patients and US pivotal trial data for EndeavorRx for adults. Finally we expect pivotal clinical trial data for Japan in pediatric patients released in 2H 2023. Additional indications under development include autism-spectrum disorder and multiple sclerosis.